Molecular Formula | C17H11ClN4O
|
Molar Mass | 322.75 |
Density | 1.513±0.06 g/cm3(Predicted) |
Boling Point | 511.0±50.0 °C(Predicted) |
Solubility | DMSO: >3mg/mL at ~60°C, clear (with warming for 2 minutes) |
Appearance | solid |
Color | yellow |
pKa | 11.75±0.43(Predicted) |
Storage Condition | 2-8°C |
In vitro study | PS-1145 blocks TNFalpha-induced NF-kappaB activation by inhibiting IkappaBalpha phosphorylation and IL-6 protects against Dex-induced apoptosis. PS-1145 also inhibited paracrine MM cell growth and IL-6 secretion caused by MM cell adhesion in BMSCs. In human primary CD4 (T) cells, PS-1145 abrogated cell proliferation and blocked the activation of nf-1b and AP-1 transcription factors through the participation of CD3 and CD28 co-receptors. |
In vivo study | In male Wistar rats with DMBA-induced skin tumors, PS-1145 (50 mg/kg, I. v.) by upregulating p53, activating caspases, and down-regulating NF-κB and VEGF factors, tumor cell apoptosis is enhanced, thereby inducing tumor progression. |